logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9193716 B1

PDFFull Text
Date of Patent:
Nov. 24, 2015

Filed:

Oct. 29, 2013

S1p receptors modulators and their use thereof

Applicant:

Akaal Pharma Pty Ltd., Bundoora, AU;

Inventors:

Gurmit S. Gill, Craigieburn, AU;

Damian W. Grobelny, Watsonia North, AU;

Assignee:

Akaal Pharma PTY LTD., Bundoora, AU;

Attorneys:

Cooley LLP

Heidi A. Erlacher

Lian Ouyang

Primary Examiner:

Craig Ricci

Int. Cl.
CPC ...
A61K 31/00 (2006.01); C07D 413/04 (2006.01); A61K 31/16 (2006.01); A61K 31/18 (2006.01); A61K 31/343 (2006.01); A61K 31/382 (2006.01); A61K 31/397 (2006.01); A61K 31/403 (2006.01); A61K 31/41 (2006.01); A61K 31/4164 (2006.01); C07C 33/26 (2006.01); C07C 215/10 (2006.01); C07C 215/14 (2006.01); C07C 215/16 (2006.01); C07C 229/16 (2006.01); C07C 275/24 (2006.01); C07C 275/28 (2006.01); C07C 281/06 (2006.01); C07D 205/04 (2006.01); C07D 209/04 (2006.01); C07D 209/08 (2006.01); C07D 215/18 (2006.01); C07D 233/32 (2006.01); C07D 241/12 (2006.01); C07D 257/04 (2006.01); C07D 295/104 (2006.01); C07D 307/79 (2006.01); C07D 307/81 (2006.01); C07D 311/22 (2006.01); C07D 333/04 (2006.01); C07D 333/20 (2006.01); C07D 413/10 (2006.01); C07D 413/14 (2006.01); C07F 9/09 (2006.01); C07F 9/6558 (2006.01);
U.S. Cl.
CPC ...
C07D 413/04 (2013.01); A61K 31/16 (2013.01); A61K 31/18 (2013.01); A61K 31/343 (2013.01); A61K 31/382 (2013.01); A61K 31/397 (2013.01); A61K 31/403 (2013.01); A61K 31/41 (2013.01); A61K 31/4164 (2013.01); C07C 33/26 (2013.01); C07C 215/10 (2013.01); C07C 215/14 (2013.01); C07C 215/16 (2013.01); C07C 229/16 (2013.01); C07C 275/24 (2013.01); C07C 275/28 (2013.01); C07C 281/06 (2013.01); C07D 205/04 (2013.01); C07D 209/04 (2013.01); C07D 209/08 (2013.01); C07D 215/18 (2013.01); C07D 233/32 (2013.01); C07D 241/12 (2013.01); C07D 257/04 (2013.01); C07D 295/104 (2013.01); C07D 307/79 (2013.01); C07D 307/81 (2013.01); C07D 311/22 (2013.01); C07D 333/04 (2013.01); C07D 333/20 (2013.01); C07D 413/10 (2013.01); C07D 413/14 (2013.01); C07F 9/094 (2013.01); C07F 9/65586 (2013.01); C07C 2102/42 (2013.01); C07C 2103/74 (2013.01);
Abstract

The invention relates to novel compounds that have SIP receptor modulating activity. Further, the invention relates to a pharmaceutical comprising at least one compound of the invention for the treatment of diseases and/or conditions caused by or associated with inappropriate SIP receptor modulating activity or expression, for example, autoimmune response. A further aspect of the invention relates to the use of a pharmaceutical comprising at least one compound of the invention for the manufacture of a medicament for the treatment of diseases and/or conditions caused by or associated with inappropriate SIP receptor modulating activity or expression such as autoimmune response.

Find Patent Forward Citations

Loading…